Cargando…

Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network

Objectives: Data on abatacept (ABA) persistence in routine practice are limited. We aimed to study ABA persistence rates at 12 months, according to the date of initiation, and to analyze the factors associated with persistence at 12 months. Methods: We performed an observational, ambispective, multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Salmon, Jean-Hugues, Letarouilly, Jean-Guillaume, Goëb, Vincent, Kanagaratnam, Lukshe, Coquerelle, Pascal, Guyot, Marie-Hélène, Houvenagel, Eric, Lecuyer, Nicolas, Marguerie, Laurent, Morel, Gauthier, Baudens, Guy, Gervais, Elisabeth, Flipo, René-Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290911/
https://www.ncbi.nlm.nih.gov/pubmed/32438597
http://dx.doi.org/10.3390/jcm9051528
_version_ 1783545786889404416
author Salmon, Jean-Hugues
Letarouilly, Jean-Guillaume
Goëb, Vincent
Kanagaratnam, Lukshe
Coquerelle, Pascal
Guyot, Marie-Hélène
Houvenagel, Eric
Lecuyer, Nicolas
Marguerie, Laurent
Morel, Gauthier
Baudens, Guy
Gervais, Elisabeth
Flipo, René-Marc
author_facet Salmon, Jean-Hugues
Letarouilly, Jean-Guillaume
Goëb, Vincent
Kanagaratnam, Lukshe
Coquerelle, Pascal
Guyot, Marie-Hélène
Houvenagel, Eric
Lecuyer, Nicolas
Marguerie, Laurent
Morel, Gauthier
Baudens, Guy
Gervais, Elisabeth
Flipo, René-Marc
author_sort Salmon, Jean-Hugues
collection PubMed
description Objectives: Data on abatacept (ABA) persistence in routine practice are limited. We aimed to study ABA persistence rates at 12 months, according to the date of initiation, and to analyze the factors associated with persistence at 12 months. Methods: We performed an observational, ambispective, multi-center study from January 2008 to July 2016, based on the French-RIC Network. We defined three groups of patients followed up for rheumatoid arthritis (RA), according to the date of initiation of ABA therapy: Group 1 (from 2007 to 31 July 2010: ABA indicated after anti-TNF failure); Group 2 (from 1 August 2010 to 31 March 2014: ABA indicated after conventional antirheumatic drugs failure); Group 3 (from 1 April 2014 to 1 July 2016: ABA available by the subcutaneous injection). Results: Among 517 patients who initiated ABA, drug persistence at 12 months was 68%. The only factor significantly associated with persistence rate at 12 months was C-reactive protein (CRP) < 10 mg/L at ABA initiation (odds ratio (OR) 0.6, 95% confidence interval 0.3–0.9; p = 0.0016). There was no significant difference in drug persistence according to date of initiation, the line of biological disease-modifying antirheumatic drugs (bDMARD) therapy or the route of administration. Conclusions: In routine practice, over time, ABA has come to be initiated earlier in the course of therapy for RA in France. Abatacept persistence is similar to that reported in the Orencia Rheumatoid Arthritis (ORA) registry, and does not differ according to the date of initiation. The only factor found to be associated with the persistence rate at 12 months was CRP < 10 mg/L at ABA initiation.
format Online
Article
Text
id pubmed-7290911
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72909112020-06-17 Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network Salmon, Jean-Hugues Letarouilly, Jean-Guillaume Goëb, Vincent Kanagaratnam, Lukshe Coquerelle, Pascal Guyot, Marie-Hélène Houvenagel, Eric Lecuyer, Nicolas Marguerie, Laurent Morel, Gauthier Baudens, Guy Gervais, Elisabeth Flipo, René-Marc J Clin Med Article Objectives: Data on abatacept (ABA) persistence in routine practice are limited. We aimed to study ABA persistence rates at 12 months, according to the date of initiation, and to analyze the factors associated with persistence at 12 months. Methods: We performed an observational, ambispective, multi-center study from January 2008 to July 2016, based on the French-RIC Network. We defined three groups of patients followed up for rheumatoid arthritis (RA), according to the date of initiation of ABA therapy: Group 1 (from 2007 to 31 July 2010: ABA indicated after anti-TNF failure); Group 2 (from 1 August 2010 to 31 March 2014: ABA indicated after conventional antirheumatic drugs failure); Group 3 (from 1 April 2014 to 1 July 2016: ABA available by the subcutaneous injection). Results: Among 517 patients who initiated ABA, drug persistence at 12 months was 68%. The only factor significantly associated with persistence rate at 12 months was C-reactive protein (CRP) < 10 mg/L at ABA initiation (odds ratio (OR) 0.6, 95% confidence interval 0.3–0.9; p = 0.0016). There was no significant difference in drug persistence according to date of initiation, the line of biological disease-modifying antirheumatic drugs (bDMARD) therapy or the route of administration. Conclusions: In routine practice, over time, ABA has come to be initiated earlier in the course of therapy for RA in France. Abatacept persistence is similar to that reported in the Orencia Rheumatoid Arthritis (ORA) registry, and does not differ according to the date of initiation. The only factor found to be associated with the persistence rate at 12 months was CRP < 10 mg/L at ABA initiation. MDPI 2020-05-19 /pmc/articles/PMC7290911/ /pubmed/32438597 http://dx.doi.org/10.3390/jcm9051528 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Salmon, Jean-Hugues
Letarouilly, Jean-Guillaume
Goëb, Vincent
Kanagaratnam, Lukshe
Coquerelle, Pascal
Guyot, Marie-Hélène
Houvenagel, Eric
Lecuyer, Nicolas
Marguerie, Laurent
Morel, Gauthier
Baudens, Guy
Gervais, Elisabeth
Flipo, René-Marc
Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
title Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
title_full Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
title_fullStr Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
title_full_unstemmed Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
title_short Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
title_sort actual persistence of abatacept in rheumatoid arthritis: results of the french-ric network
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290911/
https://www.ncbi.nlm.nih.gov/pubmed/32438597
http://dx.doi.org/10.3390/jcm9051528
work_keys_str_mv AT salmonjeanhugues actualpersistenceofabataceptinrheumatoidarthritisresultsofthefrenchricnetwork
AT letarouillyjeanguillaume actualpersistenceofabataceptinrheumatoidarthritisresultsofthefrenchricnetwork
AT goebvincent actualpersistenceofabataceptinrheumatoidarthritisresultsofthefrenchricnetwork
AT kanagaratnamlukshe actualpersistenceofabataceptinrheumatoidarthritisresultsofthefrenchricnetwork
AT coquerellepascal actualpersistenceofabataceptinrheumatoidarthritisresultsofthefrenchricnetwork
AT guyotmariehelene actualpersistenceofabataceptinrheumatoidarthritisresultsofthefrenchricnetwork
AT houvenageleric actualpersistenceofabataceptinrheumatoidarthritisresultsofthefrenchricnetwork
AT lecuyernicolas actualpersistenceofabataceptinrheumatoidarthritisresultsofthefrenchricnetwork
AT marguerielaurent actualpersistenceofabataceptinrheumatoidarthritisresultsofthefrenchricnetwork
AT morelgauthier actualpersistenceofabataceptinrheumatoidarthritisresultsofthefrenchricnetwork
AT baudensguy actualpersistenceofabataceptinrheumatoidarthritisresultsofthefrenchricnetwork
AT gervaiselisabeth actualpersistenceofabataceptinrheumatoidarthritisresultsofthefrenchricnetwork
AT fliporenemarc actualpersistenceofabataceptinrheumatoidarthritisresultsofthefrenchricnetwork